TLCVision to incorporate TearLab Osmolarity System to study DED in refractive surgery centers

NewsGuard 100/100 Score

OccuLogix, Inc., dba TearLab Corporation ("TearLab") (Nasdaq:TEAR) (TSX:TLB), announced today that TLCVision Corporation, North America's premier eye care services company, will be incorporating the TearLab™ Osmolarity System ("TearLab System") in eight of its U.S. refractive surgery centers to study Dry Eye Disease ("DED") symptoms as they relate to LASIK surgery.

The TearLab System is intended to measure the osmolarity of human tears to aid in the diagnosis of DED in conjunction with other methods of clinical evaluation. Using a novel lab-on-a-chip approach, the TearLab System requires less than 50 nL (nanoliters) of tear fluid and displays quantitative osmolarity results in less than 30 seconds. By requiring such a small amount of tears, the TearLab System eliminates the challenges that previously prevented point-of-care osmolarity testing. In addition, it is simple enough to be operated by a technician, greatly improving patient throughput either an office or center setting.

In keeping with its ongoing commitment to provide the best possible outcomes and the highest levels of care for patients, TLCVision will be using the TearLab System to study both pre- and post-operative tear osmolarity levels and treatments with the goal of improving outcomes and reducing post-operative DED symptoms.

Michael A. Lemp, MD, TearLab's chief medical officer, commented, "Tear hyper-osmolarity is a core mechanism in DED causing damage to the ocular surface and tear osmolarity is a reliable, highly sensitive and specific test for the clinical diagnosis of this disease and a great tool for doctors and a major benefit to patients."

James B. Tiffany, President and Chief Operating Officer of TLCVision, commented, "TLCVision's ongoing commitment to clinical services, quality assurance and patient outcomes are unparalleled as the industry leader. We believe that the incorporation of the TearLab System has the potential to improve patient screening, counseling and most significantly the quality of surgical outcome. 

Source:

OccuLogix, Inc. dba TearLab Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Delirium linked to tripled dementia risk in older adults, Australian study finds